294 related articles for article (PubMed ID: 28211941)
1. Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee.
Katzenstein HM; Furman WL; Malogolowkin MH; Krailo MD; McCarville MB; Towbin AJ; Tiao GM; Finegold MJ; Ranganathan S; Dunn SP; Langham MR; McGahren ED; Rodriguez-Galindo C; Meyers RL
Cancer; 2017 Jun; 123(12):2360-2367. PubMed ID: 28211941
[TBL] [Abstract][Full Text] [Related]
2. Vincristine/irinotecan/temsirolimus upfront window treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 Study Committee.
Thompson PA; Malogolowkin MH; Furman WL; Piao J; Krailo MD; Chung N; Brock L; Towbin AJ; McCarville EB; Finegold MJ; Ranganathan S; Dunn SP; Langham MR; McGahren ED; Tiao GM; Weldon CB; O'Neill AF; Rodriguez-Galindo C; Meyers RL; Katzenstein HM
Pediatr Blood Cancer; 2023 Jul; 70(7):e30365. PubMed ID: 37073741
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.
O'Neill AF; Towbin AJ; Krailo MD; Xia C; Gao Y; McCarville MB; Meyers RL; McGahren ED; Tiao GM; Dunn SP; Langham MR; Weldon CB; Finegold MJ; Ranganathan S; Furman WL; Malogolowkin M; Rodriguez-Galindo C; Katzenstein HM
J Clin Oncol; 2017 Oct; 35(30):3465-3473. PubMed ID: 28892430
[TBL] [Abstract][Full Text] [Related]
4. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial.
Katzenstein HM; Langham MR; Malogolowkin MH; Krailo MD; Towbin AJ; McCarville MB; Finegold MJ; Ranganathan S; Dunn S; McGahren ED; Tiao GM; O'Neill AF; Qayed M; Furman WL; Xia C; Rodriguez-Galindo C; Meyers RL
Lancet Oncol; 2019 May; 20(5):719-727. PubMed ID: 30975630
[TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group.
Ortega JA; Douglass EC; Feusner JH; Reynolds M; Quinn JJ; Finegold MJ; Haas JE; King DR; Liu-Mares W; Sensel MG; Krailo MD
J Clin Oncol; 2000 Jul; 18(14):2665-75. PubMed ID: 10894865
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL).
Zsíros J; Brugières L; Brock P; Roebuck D; Maibach R; Child M; Morland B; Casanova M; Pariente D; Paris C; de Camargo B; Ronghe M; Zimmermann A; Plaschkes J; Czauderna P; Perilongo G
Eur J Cancer; 2012 Dec; 48(18):3456-64. PubMed ID: 22835780
[TBL] [Abstract][Full Text] [Related]
7. Addition of Vincristine and Irinotecan to Standard Therapy in a Patient With Refractory High-risk Hepatoblastoma Achieving Long-term Relapse-free Survival.
Powers JM; Pacheco MM; Wickiser JE
J Pediatr Hematol Oncol; 2019 Apr; 41(3):e171-e173. PubMed ID: 29668545
[TBL] [Abstract][Full Text] [Related]
8. Vincristine and irinotecan in children with relapsed hepatoblastoma: a single-institution experience.
Zhang YT; Feng LH; Zhong XD; Wang LZ; Chang J
Pediatr Hematol Oncol; 2015 Feb; 32(1):18-25. PubMed ID: 24852330
[TBL] [Abstract][Full Text] [Related]
9. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma.
Malogolowkin MH; Katzenstein H; Krailo MD; Chen Z; Bowman L; Reynolds M; Finegold M; Greffe B; Rowland J; Newman K; Womer RB; London WB; Castleberry RP
J Clin Oncol; 2006 Jun; 24(18):2879-84. PubMed ID: 16782927
[TBL] [Abstract][Full Text] [Related]
10. Survival after liver transplantation for hepatoblastoma: a 2-center experience.
Browne M; Sher D; Grant D; Deluca E; Alonso E; Whitington PF; Superina RA
J Pediatr Surg; 2008 Nov; 43(11):1973-81. PubMed ID: 18970927
[TBL] [Abstract][Full Text] [Related]
11. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
12. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children's Cancer Group.
Van Tornout JM; Buckley JD; Quinn JJ; Feusner JH; Krailo MD; King DR; Hammond GD; Ortega JA
J Clin Oncol; 1997 Mar; 15(3):1190-7. PubMed ID: 9060563
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies.
Trobaugh-Lotrario AD; Katzenstein HM
Pediatr Blood Cancer; 2012 Nov; 59(5):809-12. PubMed ID: 22648979
[TBL] [Abstract][Full Text] [Related]
14. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
Pappo AS; Lyden E; Breitfeld P; Donaldson SS; Wiener E; Parham D; Crews KR; Houghton P; Meyer WH;
J Clin Oncol; 2007 Feb; 25(4):362-9. PubMed ID: 17264331
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study.
Zsíros J; Maibach R; Shafford E; Brugieres L; Brock P; Czauderna P; Roebuck D; Childs M; Zimmermann A; Laithier V; Otte JB; de Camargo B; MacKinlay G; Scopinaro M; Aronson D; Plaschkes J; Perilongo G
J Clin Oncol; 2010 May; 28(15):2584-90. PubMed ID: 20406943
[TBL] [Abstract][Full Text] [Related]
16. Current chemotherapeutic approaches for hepatoblastoma.
Watanabe K
Int J Clin Oncol; 2013 Dec; 18(6):955-61. PubMed ID: 24052132
[TBL] [Abstract][Full Text] [Related]
17. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study.
Zsiros J; Brugieres L; Brock P; Roebuck D; Maibach R; Zimmermann A; Childs M; Pariente D; Laithier V; Otte JB; Branchereau S; Aronson D; Rangaswami A; Ronghe M; Casanova M; Sullivan M; Morland B; Czauderna P; Perilongo G;
Lancet Oncol; 2013 Aug; 14(9):834-42. PubMed ID: 23831416
[TBL] [Abstract][Full Text] [Related]
18. [Treatment outcome of 100 patients with hepatoblastoma based on a new risk stratification].
Zhen ZZ; Liu JC; Zhou L; Xu Z; Zhang ZC; Sun FF; Lu SY; Zhu J; Wang J; Huang JT; Sun XF
Zhonghua Zhong Liu Za Zhi; 2021 Feb; 43(2):228-232. PubMed ID: 33601490
[No Abstract] [Full Text] [Related]
19. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration.
Meyers RL; Maibach R; Hiyama E; Häberle B; Krailo M; Rangaswami A; Aronson DC; Malogolowkin MH; Perilongo G; von Schweinitz D; Ansari M; Lopez-Terrada D; Tanaka Y; Alaggio R; Leuschner I; Hishiki T; Schmid I; Watanabe K; Yoshimura K; Feng Y; Rinaldi E; Saraceno D; Derosa M; Czauderna P
Lancet Oncol; 2017 Jan; 18(1):122-131. PubMed ID: 27884679
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study.
Katzenstein HM; Malogolowkin MH; Krailo MD; Piao J; Towbin AJ; McCarville MB; Tiao GM; Dunn SP; Langham MR; McGahren ED; Finegold MJ; Ranganathan S; Weldon CB; Thompson PA; Trobaugh-Lotrario AD; O'Neill AF; Furman WL; Chung N; Randazzo J; Rodriguez-Galindo C; Meyers RL
Cancer; 2022 Mar; 128(5):1057-1065. PubMed ID: 34762296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
